Aliases & Classifications for Pituitary Tumors

MalaCards integrated aliases for Pituitary Tumors:

Name: Pituitary Tumors 54 55 43
Pituitary Neoplasms 73

External Ids:

UMLS 73 C0032019

Summaries for Pituitary Tumors

NINDS : 54 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to prolactin producing pituitary tumor and tsh producing pituitary tumor. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Hydrocortisone and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

MedlinePlus : 43 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them. The most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. This can cause endocrine diseases such as Cushing's syndrome and hyperthyroidism. Symptoms of pituitary tumors include Headaches Vision problems Nausea and vomiting Problems caused by the production of too many hormones Pituitary tumors are usually curable. Treatment is often surgery to remove the tumor. Other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 33.8 PRL SST
2 tsh producing pituitary tumor 33.2 GH1 POMC PRL SST
3 acth-secreting pituitary adenoma 32.1 POMC PRL
4 gigantism 32.0 AIP GH1 PRL
5 empty sella syndrome 32.0 GH1 IGF1 POMC PRL
6 pituitary apoplexy 31.9 AIP POMC PRL
7 pituitary adenoma 1, multiple types 31.8 AIP GH1 IGF1 PRL SST
8 hormone producing pituitary cancer 31.6 AIP GNAS IGF1 MEN1 SST SSTR5
9 galactorrhea 30.6 IGF1 PRL
10 hyperthyroidism 30.0 GH1 GNAS PRL SST
11 multiple endocrine neoplasia, type i 30.0 GNAS MEN1 PRL SST
12 hyperprolactinemia 30.0 GH1 IGF1 POMC PRL SST
13 ovarian disease 29.9 IGF1 PRL VEGFA
14 pituitary gland disease 29.9 AIP GH1 IGF1 MEN1 POMC POU1F1
15 thyroid cancer 29.8 GNAS POMC SST VEGFA
16 lymphocytic hypophysitis 29.8 GH1 POMC
17 insulin-like growth factor i 29.8 GH1 IGF1 PRL SST
18 non-functioning pituitary adenoma 29.8 GH1 SST
19 adenohypophysitis 29.7 GH1 POMC PRL
20 conn's syndrome 29.6 GH1 GNAS MEN1 POMC PRL SST
21 chiasmal syndrome 29.5 POMC PRL SST
22 nelson syndrome 29.5 POMC PRL SST
23 pituitary hypoplasia 29.4 POU1F1 PRL
24 carney complex variant 29.4 AIP GNAS MEN1
25 small cell cancer of the lung 29.4 POMC RB1 SST
26 pituitary carcinoma 29.3 GNAS POMC PRL SST
27 craniopharyngioma 29.3 GH1 IGF1 POU1F1 PRL PROP1
28 mccune-albright syndrome 29.3 GH1 GNAS IGF1 PRL SST
29 acromegaly 29.2 AIP GH1 GNAS IGF1 MEN1 POMC
30 hypopituitarism 29.0 GH1 IGF1 POMC POU1F1 PRL PROP1
31 adenoma 28.9 AIP GH1 GNAS IGF1 MEN1 POMC
32 hypothyroidism 28.8 GH1 GNAS IGF1 POMC POU1F1 PRL
33 functioning pituitary adenoma 28.8 GH1 MEN1 POMC PRL SST SSTR5
34 secondary adrenal insufficiency 11.3
35 posterior pituitary gland neoplasm 11.0
36 acth-independent macronodular adrenal hyperplasia 11.0
37 primary pigmented nodular adrenocortical disease 11.0
38 fibrous dysplasia/mccune-albright syndrome 10.2 GH1 PRL
39 chronic mountain sickness 10.2 SST VEGFA
40 angiodysplasia 10.2 SST VEGFA
41 ovarian cyst 10.2 PRL VEGFA
42 villous adenoma 10.2 GNAS SST
43 amenorrhea 10.2
44 mammographic density 10.2 IGF1 PRL
45 marasmus 10.2 GH1 IGF1
46 spinocerebellar degeneration 10.2 PRL SST
47 cone-rod dystrophy 12 10.2 GH1 IGF1
48 pancreatic somatostatinoma 10.2 MEN1 SST
49 isolated growth hormone deficiency, type ib 10.1 GH1 IGF1
50 pancreas adenocarcinoma 10.1 GNAS SST VEGFA

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.22 AIP GNAS IGF1 MEN1 POMC POU1F1
2 homeostasis/metabolism MP:0005376 10.21 AIP GNAS IGF1 MEN1 POMC POU1F1
3 growth/size/body region MP:0005378 10.2 AIP GNAS IGF1 MEN1 POMC POU1F1
4 cellular MP:0005384 10.1 AIP GNAS IGF1 MEN1 POMC POU1F1
5 immune system MP:0005387 10.06 GNAS IGF1 MEN1 POMC POU1F1 PRL
6 mortality/aging MP:0010768 9.96 AIP GNAS IGF1 MEN1 POMC POU1F1
7 integument MP:0010771 9.91 AIP GNAS IGF1 POMC PRL RB1
8 liver/biliary system MP:0005370 9.87 AIP GNAS MEN1 POMC PRL RB1
9 neoplasm MP:0002006 9.76 AIP GNAS IGF1 MEN1 POMC PRL
10 nervous system MP:0003631 9.65 GNAS IGF1 MEN1 POMC POU1F1 PRL
11 reproductive system MP:0005389 9.17 IGF1 MEN1 POU1F1 PRL PROP1 RB1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
2
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
3
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
6
Ibuprofen Approved Phase 4 15687-27-1 3672
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
11
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
12
Pasireotide Approved Phase 4,Phase 3,Phase 2 396091-73-9 9941444
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Zinc Approved, Investigational Phase 4 7440-66-6
15
Liraglutide Approved Phase 4 204656-20-2 44147092
16 lanreotide Approved Phase 4,Phase 3 108736-35-2
17
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
18
Cefdinir Approved Phase 4 91832-40-5 6915944
19
leucovorin Approved Phase 4,Phase 1 58-05-9 6006 143
20
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
21
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
22
Cefazolin Approved Phase 4 25953-19-9 656510 33255
23
Sulfamethoxazole Approved Phase 4 723-46-6 5329
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
25
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Adrenergic alpha-Agonists Phase 4,Not Applicable
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Hydrocortisone-17-butyrate Phase 4,Not Applicable
30 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
31 Adrenergic Agents Phase 4,Not Applicable
32 Hypnotics and Sedatives Phase 4,Phase 1,Not Applicable
33 Analgesics, Non-Narcotic Phase 4,Not Applicable
34 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1,Not Applicable
35 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
36 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
37 Anesthetics Phase 4,Phase 1,Not Applicable
38 Adrenergic Agonists Phase 4,Not Applicable
39 Analgesics Phase 4,Not Applicable
40 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
41 Cortisol succinate Phase 4,Phase 3,Phase 2,Not Applicable
42 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 glucocorticoids Phase 4,Phase 2,Phase 1,Not Applicable
44 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Incretins Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
49 Antirheumatic Agents Phase 4,Not Applicable
50 Narcotics Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
4 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
5 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
6 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
7 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
8 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
9 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
10 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
11 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
12 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
13 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
14 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
15 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
16 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
17 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
18 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
19 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
20 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
21 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
22 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
23 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
24 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
25 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
26 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
27 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
28 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
29 Open-label Treatment in Cushing's Syndrome Not yet recruiting NCT03621280 Phase 3 Levoketoconazole
30 Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Terminated NCT00642421 Phase 3 C2L-OCT-01 PR, 10 or 20 mg;C2L-OCT-01 PR, 20 mg
31 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
32 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
33 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
34 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
35 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
36 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
37 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
38 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
39 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
40 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
41 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
42 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
43 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
44 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
45 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
46 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
47 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
48 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
49 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
50 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

MalaCards organs/tissues related to Pituitary Tumors:

41
Pituitary, Brain, Testes, Thyroid, Hypothalamus, Ovary, Adrenal Gland

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 1017)
# Title Authors Year
1
Baculovirus-based gene silencing of Humanin for the treatment of pituitary tumors. ( 29352443 )
2018
2
The role of galectin-3 in the tumorigenesis and progression of pituitary tumors. ( 29545898 )
2018
3
Advances and controversies in the classification and grading of pituitary tumors. ( 29858984 )
2018
4
Detection of circulating tumor cells in patients with pituitary tumors. ( 29587659 )
2018
5
Genomic Alterations in Sporadic Pituitary Tumors. ( 29396598 )
2018
6
Management of nonfunctioning pituitary tumors: radiotherapy. ( 29372392 )
2018
7
Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors. ( 29500747 )
2018
8
Excellence in the treatment of patients with pituitary tumors. ( 29124563 )
2018
9
Transsphenoidal Surgery for Pituitary Tumors and Other Sellar Masses. ( 29056398 )
2018
10
Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET). ( 29504817 )
2018
11
Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application. ( 29464548 )
2018
12
Headaches in Patients with Pituitary Tumors: a Clinical Conundrum. ( 29974273 )
2018
13
Endoscopic Endo-Nasal Trans-Sphenoidal Excision of Pituitary Tumors: An Institutional Experience. ( 29456951 )
2018
14
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions. ( 29963012 )
2018
15
Expression of MMP-9, PTTG, HMGA2, and Ki-67 in ACTH-secreting pituitary tumors and their association with tumor recurrence. ( 29432944 )
2018
16
Clinical Presentation and Management of Headache in Pituitary Tumors. ( 29904889 )
2018
17
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. ( 29535142 )
2018
18
Lnc-SNHG1 Activates the TGFBR2/SMAD3 and RAB11A/Wnt/β-Catenin Pathway by Sponging MiR-302/372/373/520 in Invasive Pituitary Tumors. ( 30048990 )
2018
19
Three-Dimensional Volumetric Segmentation of Pituitary Tumors: Assessment of Inter-rater Agreement and Comparison with Conventional Geometric Equations. ( 30210975 )
2018
20
Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. ( 30246233 )
2018
21
The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. ( 30273935 )
2018
22
Effectiveness of intraoperative visual evoked potential in avoiding visual deterioration during endonasal transsphenoidal surgery for pituitary tumors. ( 30288662 )
2018
23
Endoscopic endonasal approach combined with a simultaneous transcranial approach for giant pituitary tumors. ( 30336293 )
2018
24
Medical therapy for non-functioning pituitary tumors-a critical approach. ( 30368687 )
2018
25
Variability in Clinical Presentation and Pathologic Implications of Ectopic Pituitary Tumors: Critical Review of the Literature. ( 30404064 )
2018
26
Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey. ( 30456434 )
2018
27
Predictive Factors for Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery in Patients with Nonfunctioning Pituitary Tumors: A Retrospective Observational Study. ( 30465961 )
2018
28
Use of intraoperative intracavitary (direct-contact) ultrasound for resection control in transsphenoidal surgery for pituitary tumors: evaluation of a microsurgical series. ( 30483982 )
2018
29
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance). ( 30531551 )
2018
30
Evaluation of bendable surgical suction devices made of shape-memory alloy for the endonasal transsphenoid removal of pituitary tumors. ( 30540892 )
2018
31
MicroRNA‑16/VEGFR2/p38/NF‑κB signaling pathway regulates cell growth of human pituitary neoplasms. ( 29399695 )
2018
32
Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients. ( 28789441 )
2017
33
Neuroretinal evaluation using optical coherence tomography in patients affected by pituitary tumors. ( 28447589 )
2017
34
Overview of the 2017 WHO Classification of Pituitary Tumors. ( 28766057 )
2017
35
First Report of Coexistence of Two Ectopic Pituitary Tumors: Rathke Cleft Cyst and Silent Adrenocorticotropic Hormone Adenoma. ( 28532906 )
2017
36
A Comparison of Dexmedetomidine and Clonidine in Attenuating the Hemodynamic Responses at Various Surgical Stages in Patients Undergoing Elective Transnasal Transsphenoidal Resection of Pituitary Tumors. ( 29284879 )
2017
37
Prognostic factors of regrowth in nonfunctioning pituitary tumors. ( 29288467 )
2017
38
Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. ( 28711607 )
2017
39
Transient Exacerbation of Nasal Symptoms following Endoscopic Transsphenoidal Surgery for Pituitary Tumors: A Prospective Study. ( 28593114 )
2017
40
MicroRNAs in pituitary tumors. ( 28089822 )
2017
41
FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. ( 27966451 )
2017
42
Authors' Reply: Comprehensive neuro-ophthalmological assessment in pituitary tumors. ( 28488670 )
2017
43
Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. ( 28432119 )
2017
44
Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. ( 29043561 )
2017
45
Non-functioning pituitary tumors: any special considerations during pregnancy? ( 29265782 )
2017
46
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. ( 28120505 )
2017
47
Full-field perimetry in pituitary tumors. ( 28488669 )
2017
48
Recent Progress in the Medical Therapy of Pituitary Tumors. ( 28685507 )
2017
49
The Stem Cell Connection of Pituitary Tumors. ( 29255445 )
2017
50
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. ( 28486603 )
2017

Variations for Pituitary Tumors

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 GH1 GNAS IGF1 POMC PRL SST
2 endosome lumen GO:0031904 9.16 GH1 PRL
3 chromatin GO:0000785 9.13 MEN1 POU1F1 RB1
4 secretory granule GO:0030141 8.8 POMC PRL VEGFA

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 MEN1 POU1F1 PROP1 RB1 VEGFA
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 GH1 IGF1 VEGFA
3 regulation of multicellular organism growth GO:0040014 9.57 IGF1 PRL
4 positive regulation of JAK-STAT cascade GO:0046427 9.56 GH1 PRL
5 positive regulation of receptor internalization GO:0002092 9.55 GH1 VEGFA
6 negative regulation of cell proliferation GO:0008285 9.55 MEN1 POU1F1 RB1 SST SSTR5
7 tissue homeostasis GO:0001894 9.54 GNAS RB1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 GH1 IGF1 VEGFA
9 myoblast differentiation GO:0045445 9.52 IGF1 RB1
10 positive regulation of epithelial cell proliferation GO:0050679 9.5 IGF1 PRL VEGFA
11 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 IGF1 MEN1 POMC POU1F1 PROP1 RB1
12 positive regulation of transcription regulatory region DNA binding GO:2000679 9.49 IGF1 RB1
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 GH1 PRL
14 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GH1 IGF1
15 adenohypophysis development GO:0021984 9.4 POU1F1 PROP1
16 somatotropin secreting cell differentiation GO:0060126 9.26 POU1F1 PROP1
17 regulation of signaling receptor activity GO:0010469 9.1 GH1 IGF1 POMC PRL SST VEGFA

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 GH1 IGF1 VEGFA
2 insulin-like growth factor receptor binding GO:0005159 9.16 GNAS IGF1
3 hormone activity GO:0005179 9.02 GH1 IGF1 POMC PRL SST
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....